COMP <GO>
SOLV vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
Solventum Corporation (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: SOLV 3
— JNJ 11
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: JNJ
LAST: $81.33 (-2.67%) • MKT CAP: $14.22B
balance-sheet
2.25
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SOLV VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SOLV | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 53.50% | 67.90% | -14.40 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.70% | 25.50% | -6.80 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.3x | 18.5x | -11.20 | SOLV | /valuation <GO> |
| Free Cash Flow Yield | -0.07% | 2.97% | -3.04 | JNJ | /fcf-yield <GO> |
| Operating Margin | 26.20% | 34.70% | -8.50 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 18.70% | 28.50% | -9.80 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 0.90% | 6.00% | -5.10 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 2.25 | 5.59 | -3.34 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.20% | -0.10 | SOLV | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.3 | 60.4 | -25.10 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 1.08 | -0.02 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.5x | 23.0x | -14.50 | SOLV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.22B | $662.49B | -$648.27B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SOLV REV | JNJ REV | SOLV GROSS % | JNJ GROSS % | SOLV FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.32B | $94.19B | 53.5% | 67.9% | -$10.0M | $19.70B |
| FY 2024 | $8.25B | $88.82B | 55.6% | 69.1% | $805.0M | $19.84B |
| FY 2023 | $8.20B | $85.16B | 44.0% | 44.0% | $1.55B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SOLV // BETA 1.06
JNJ // BETA 1.08